Literature DB >> 11096518

Primary Pulmonary Hypertension.

.   

Abstract

Primary pulmonary hypertension has become a very treatable disease given the recent advances in medical therapy. Any patient with unexplained right ventricular enlargement or pulmonary hypertension needs a thorough workup to determine the cause. Patients with primary pulmonary hypertension should be referred to a specialized "Center of Excellence" to evaluate potential therapies on a case-by-case basis. Warfarin anticoagulation is generally recommended in all patients. Some patients (approximately 20%) will have a dramatic response to high doses of calcium channel blockers; the remainder are generally helped by the use of continuous intravenous prostacyclin therapy. Lung transplantation remains the final treatment option for patients in whom medical therapy fails.

Entities:  

Year:  2000        PMID: 11096518     DOI: 10.1007/s11936-000-0006-1

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  15 in total

Review 1.  Primary pulmonary hypertension.

Authors:  L J Rubin
Journal:  N Engl J Med       Date:  1997-01-09       Impact factor: 91.245

2.  Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.

Authors:  V V McLaughlin; D E Genthner; M M Panella; D M Hess; S Rich
Journal:  Ann Intern Med       Date:  1999-05-04       Impact factor: 25.391

3.  Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease.

Authors:  M Packer; N Medina; M Yushak
Journal:  J Am Coll Cardiol       Date:  1984-11       Impact factor: 24.094

4.  Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension.

Authors:  T Saji; Y Ozawa; T Ishikita; H Matsuura; N Matsuo
Journal:  Am J Cardiol       Date:  1996-07-15       Impact factor: 2.778

5.  An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension.

Authors:  G Mikhail; J Gibbs; M Richardson; G Wright; A Khaghani; N Banner; M Yacoub
Journal:  Eur Heart J       Date:  1997-09       Impact factor: 29.983

6.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

Authors:  V V McLaughlin; D E Genthner; M M Panella; S Rich
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

7.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

Review 8.  The current status of lung transplantation.

Authors:  L R Kaiser; J D Cooper
Journal:  Adv Surg       Date:  1992

9.  High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

Authors:  S Rich; B H Brundage
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

10.  Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine.

Authors:  M J Ricciardi; B P Knight; F J Martinez; M Rubenfire
Journal:  J Am Coll Cardiol       Date:  1998-10       Impact factor: 24.094

View more
  1 in total

1.  Diagnostic value of chest spiral CT scan and Doppler echocardiography compared to right heart catheterization to predict pulmonary arterial hypertension in patients with scleroderma.

Authors:  Siavash Kooranifar; Roozbeh Naghshin; Seyed Hashem Sezavar; Shokoufeh Hajsadeghi; Seyed Mehdi Talebzadeh
Journal:  Acta Biomed       Date:  2021-01-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.